Introduction
Immune thrombocytopenia (ITP), formerly known as idiopathic or immune thrombocytopenic purpura, is an acquired bleeding diathesis resulting from premature platelet destruction, reduced platelet production or a combination of both (1, 2) . Primary ITP is defined as isolated thrombocytopenia in the absence of an identified etiology or illness. Secondary ITP assumes the presence of a concurrent underlying disorder responsible for disturbed immune function leading to thrombocytopenia. The list of such disorders is extensive and may include autoimmune diseases (e.g. systemic lupus erythematosus or antiphospholipid syndrome), lymphoproliferative disorders, and chronic infections (e.g. Helicobacter pylori, human immunodeficiency virus or hepatitis C virus) in addition to many others (3) . ITP occurs across all age groups. The estimated incidence in children is approximately 1.9 to 6.4 cases per 100,000 per year and for adults 3.3 per 100,000 per year (4) .
Retrospective data, consensus statements, expert opinion and textbooks suggest that childhood and adult onset ITP have distinctly different laboratory findings and clinical features (5, 6, 7, 8, 9) .
Due to the rarity of ITP, and the paucity of prospective clinical trial data, the Intercontinental Cooperative ITP Study Group (ICIS) was founded in 1997 by an international panel of hematologists with the goal of establishing a worldwide network of physicians and researchers to collect data to better define the natural history of childhood ITP, in addition to questions concerning diagnosis and therapy, including early predictors of chronic ITP (www.itpbasel.ch). In 2002, ICIS established the Pediatric and Adult Registry on Chronic ITP (PARC ITP). This international, multi-center registry was designed to collect prospective laboratory and clinical data from children and adults with newly diagnosed ITP and to follow them continuously over time. The information in the database will be used to compare the laboratory and clinical features of pediatric and adult ITP, to analyse the heterogeneity and natural history of the disorder across the different age groups, to validate its diagnosis and management, and to identify new patient selection criteria for future trials.
This investigation is restricted to the query of the PARC ITP Registry assessing clinical findings at the time of initial diagnosis, with the aim to compare the differences between children and adults with ITP. The findings suggest that the differences observed between the two age groups are smaller than expected.
Design and Methods

Registry design
The structure of the Registry is similar to its predecessors -ICIS Registry I (10) and ICIS Registry II 
Registration process
Patients could be registered if the clinical impression of the local treating physician was that the diagnosis was consistent with ITP and the platelet count was less than 150 x 10 9 /L. The study protocol included the practice guidelines which were published at that time (6, 7, 12) , however, diagnosis, clinical criteria, and treatment decisions were left to the participating physician. A platelet count of less than 100 x 10 9 /l was not used, as the newer definitions of ITP (3) were published later.
Questionnaires
The questionnaire included demographic information, date of diagnosis, blood counts at diagnosis, Table 1 for patient characteristics.
Self-reported ethnic background of the patients is presented in Table 1 . The percentage of adults was higher in Caucasians and smaller in the other groups. In children, the male:female ratio was in favor of males, with female patients being older (p=0.001). In adults, females were more frequently seen, without a difference in age between males and females.
Co-morbidity was observed in 69/1784 children (3.9%) and in 102/340 adults (30%); (p<0.0001).
More than one co-morbid condition was reported in 1 child and in 33 adults. Splenomegaly was reported in 17 children and 1 adult, challenging the diagnosis of primary ITP. Further details of the comorbid conditions were not requested. Patients with a co-morbid condition are described in Table 1 .
Diabetes, gastrointestinal disease, arterial hypertension and thyroid disease occurred more often in adults. Cancer, cardiovascular disease, and splenomegaly were observed in both age groups at similar frequencies.
Concurrently used medications at the time of diagnosis were found more commonly in adults than children. 19 of 1784 children were taking anti-inflammatory drugs at the time of the diagnosis of ITP.
None were taking platelet antagonists, vitamin K antagonists, or other anticoagulants. In the 340 adults, 17 were prescribed anti-inflammatory medications, 11 platelet antagonists, 4 vitamin K antagonists, and 2 were taking other anticoagulants.
A family history of thrombocytopenia was identified in 42/1784 children (2%) and in 9/340 adults (3%).
Clinical signs of bleeding were assessed by location (no symptoms, cutaneous, oral cavity, nose, menstrual, gastrointestinal, urine, intracranial, muscle, and joint) and if the specific bleeding event required medicinal treatment (intravenous immunoglobulins, corticosteroids, anti-D or combination therapy) ( Table 2 ). Bleeding manifestations (any site) were observed more frequently in children (1629 patients, 91%) than in adults (236 patients, 69%) (p<0.0001).
A similar percentage of children and adults who had no reported signs of bleeding -24% (37/151 children) and 23% (24/104 adults) received some form of platelet enhancing treatment. Intracranial hemorrhage occurred in 10/1784 children (0.6%) and in 6/340 adults (1.8%) (N.S.). The mean age of children with intracranial hemorrhage was 5 and that of adults was 60 years. The outcome of these patients remains unknown. When bleeding signs were analyzed in patients with a presenting platelet count less than or equal/higher than 20x10 9 /l, a similar occurrence of bleeding was observed, except for muscle bleeds, which occurred more frequently at lower platelet counts (Figure 1 ).
The mean platelet count at diagnosis was 18.1 (range, 0-137) x 10 9 /l for children and 25.4 (range, 0-133) x 10 9 /l for adults. The distribution of the platelet count is displayed in Figure 2a . A platelet count of <20 x 10 9 /l was found more often in children (1286/1784 children, 79%), than in adults (186/340 adult patients 58%) (p<0.0001). To compare similarity or dissimilarity of the platelet count distribution between children and adults, a quantile-quantile-plot was calculated (Figure 2b ). This suggests a strong similarity of platelet counts in the low range (platelet count 0-15 x 10 9 /l) of both age groups and slightly higher platelet counts in adult compared to pediatric patients above this value. The choice of diagnostic procedure and frequency of testing differed among children and adults ( Figure 3) . Bone marrow examination, antinuclear antibody, HIV and Hepatitis C testing were performed more frequently (p<0.0001) in adults than in children. Bone marrow examinations were performed more frequently in patients treated with corticosteroids in contrast to other treatments in both children (78%) and adults (85%). Antiphospholipid antibody, platelet associated antibody and
Helicobacter pylori testing were performed in less than 50% of patients in both age groups. Laboratory test results (children versus adults) were similar for HIV (1% versus 1%), while testing for HCV (0% versus 3%) and Helicobacter pylori (17% versus 31%) was positive more often in adults (Table 3) .
Antinuclear (18% versus 10%) and platelet associated antibodies (67% versus 47%) were more frequently positive in children than in adults, whereas antiphospholipid antibodies were present in children and in adults in a similar frequency (10% versus 6%).
Management of children and adults is summarized in Figure 4 . Immunoglobulins were used more frequently in children, whereas adults received corticosteroids more frequently.
A sub-group analysis of children and adults who did not receive any platelet enhancing drug treatment at first presentation revealed 364 children (20%) and 100 adults (29%). The mean age of this subgroup was 6.2 years in children and 38. At the time of this analysis, the majority of the subjects in the Registry were children. The first ICIS registries were exclusively pediatric, consequently there was greater early involvement by pediatric investigators. However, the proportion of adult data being submitted is increasing with time, and it is expected that later queries should reflect a greater balance. Although the adult data represents only a fraction of the total, 340 subjects is a large enough sample size to make valid comparisons to the much larger pediatric population. Our data supports and confirms some previously reported observations, including the predominance of males in the pediatric age group, whereas female gender dominates among adult patients (13, 14, 15) . This analysis suggest that autoimmune disorders, which are associated with female gender (16), may be an explanation for the greater number of adult women with ITP. Reasons for the observed high proportion of males in childhood ITP remain unknown (10, 14, 15 ).
An important finding of this analysis is the great overlap in the clinical and laboratory features of ITP at first diagnosis among children and adults. Similarities are observed in presenting platelet counts, incidence and type of bleeding when platelet counts are less than 20x10 9 /l, and reported family history of thrombocytopenia. Although bleeding occurred more frequently in children than in adults, the decision to treat was similar for both age groups. The severity of bleeding events cannot be compared since bleeding scores were not requested.
Not unexpectedly, concurrent use of medication and co-morbid disorders were reported more often for adults. In both adults and children, gastrointestinal disease was the most common associated comorbid condition. Of note, 17 children were noted to have splenomegaly. The presence of comorbidities, splenomegaly, and positive family history of ITP among children and adults points to the heterogeneity of ITP and suggests that the classification into primary and secondary ITP needs critical reconsideration.
With the exception of the high incidence of co-morbid conditions in adults, greatest dissimilarities between pediatric and adult ITP were different approaches to diagnostic evaluation and treatment.
Adult patients had laboratory testing more often than children ( Figure 3) . Surprisingly, a similar proportion of children and adults were observed without active treatment, in contrast to previous published reports (6, 8) . When treatment was prescribed, intravenous immunoglobulins and anti-D were used more frequently in children, while corticosteroids dominated in adults.
A registry is a scientific tool with advantages and disadvantages. As a consequence the data collected by the PARC-ITP does have some limitations. A great advantage of a registry is the ability to use it collaboratively, in a multinational setting, to collect data from a large number of patients with rare disorders in a relatively short interval of time. The information gathered can then be used to develop scientific questions for further study, and the database adapted to focus on specific areas of study 483 (27) 379 (21) 53 (3) 56 (3) 213 (63) 55 (16) 52 (15) 6 (2) 14 ( Black bars (from left, 0%, to the right, 100%) indicate the percentage of patients in whom a given laboratory test was performed and white bars (from right, 0%, to the left, 100%) indicate the percentage of patients in whom that given test was not performed. Test results are presented in Table   3 . c = children, a = adults. 
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